Fomite

Verrica Pharmaceuticals to Host Virtual KOL Event Discussing the Approval of YCANTH™ (Cantharidin) Topical Solution for the Treatment of Molluscum on October 11, 2023

Retrieved on: 
Wednesday, September 27, 2023
KOL, Therapy, Fungal infection, Pediatric Dermatology, Inflammation, Pain, Itch, Mercedes Gonzalez, Sibling, Patient, Molluscum contagiosum, Fomite, Genetically modified bacteria, FDA, Skin, Vaccine, Dermatology, MD

The event will focus on the recent approval of YCANTH™ as the only product approved by the FDA to treat molluscum in adult and pediatric patients two years of age and older.

Key Points: 
  • The event will focus on the recent approval of YCANTH™ as the only product approved by the FDA to treat molluscum in adult and pediatric patients two years of age and older.
  • Molluscum is caused by a pox virus that produces distinctive raised, skin-toned-to-pink-colored lesions that can cause pain, inflammation, itching and bacterial infection.
  • It is easily transmitted through direct skin-to-skin contact or through fomites and can spread to other parts of the body or to other people, including siblings.
  • Without treatment, molluscum can last for an average of 13 months, and in some cases, up to five years.

Verrica Pharmaceuticals Reports Third Quarter 2022 Financial Results

Retrieved on: 
Monday, November 7, 2022
Exercise, Skin, Company, CMC, CRL, Genetically modified bacteria, Dermatology, Collaboration, Squamous cell carcinoma, Fomite, U.S. Securities and Exchange Commission, Pharmacokinetics, Inflammation, Research, GAAP, Patient, Private Securities Litigation Reform Act, Wart, Itch, Mission statement, Achievement, United, Clinical trial, Social stigma, Physician, Sibling, Table, Molluscum contagiosum, NDA, FDA, Caregiver, Income, GLOBE, Cantharidin, Technology transfer, Safety, Disease, Pain, Therapy, Pharmaceutical industry, Reinsurance, Air cargo, Torii, Piramal, Chemistry

WEST CHESTER, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the third quarter ended September 30, 2022.

Key Points: 
  • WEST CHESTER, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the third quarter ended September 30, 2022.
  • Research and development expenses were $2.9million in the third quarter of 2022, compared to $3.8 million for the same period in 2021.
  • General and administrative expenses were $3.9million in the third quarter of 2022, compared to $8.0 million for the same period in 2021.
  • As of September 30, 2022, Verrica had aggregate cash, cash equivalents, marketable securities and restricted cash of $39.5million.

Verrica Pharmaceuticals Reports Second Quarter 2022 Financial Results

Retrieved on: 
Thursday, August 11, 2022
FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, U.S. Securities and Exchange Commission, Dermatology, Hand, NDA, Table, Inflammation, GLOBE, Food, Private Securities Litigation Reform Act, CRL, Molluscum contagiosum, Disease, Achievement, Pain, Torii, Itch, Endpoint security, Laboratory of design, manufacturing and control, CMO, Company, Mission statement, Wart, Genetically modified bacteria, Therapy, Skin, Collaboration, Technology transfer, GAAP, Research, New Drug Application, Cantharidin, Social stigma, CMC, Fomite, Sibling, Pharmaceutical industry, Fine chemical, Security (finance), Reinsurance, Bank, Online gambling, Piramal, Chemistry

WEST CHESTER, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the second quarter ended June 30, 2022.

Key Points: 
  • WEST CHESTER, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the second quarter ended June 30, 2022.
  • The gross proceeds from the offering to Verrica were approximately $28.5 million, before deducting underwriting discounts and commissions and offering expenses.
  • Research and development expenses were $4.2million in the second quarter of 2022, compared to $3.4 million for the same period in 2021.
  • General and administrative expenses were $5.2million in the second quarter of 2022, compared to $7.3 million for the same period in 2021.

Enzo Biochem to Launch Monkeypox Testing Services this Week

Retrieved on: 
Thursday, August 11, 2022
FDA, Intellectual property, Monkeypox, Personal Data Privacy and Security Act of 2009, MPX, Smallpox, Industry, NYSE, GLOBE, Population, Fluid mechanics, Securities Exchange Act of 1934, Incidence, Patent, CDC, DNA, Company, Family, ENZ, Risk, Virus, Securities Act of 1933, Monkeypox virus, Fomite, Orthopoxvirus, Vaccine

NEW YORK, NY, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (Enzo or the Company), a leading biosciences and diagnostics company, announced today that its full-service clinical laboratory will begin accepting specimens for monkeypox (MPX) testing this week.

Key Points: 
  • NEW YORK, NY, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (Enzo or the Company), a leading biosciences and diagnostics company, announced today that its full-service clinical laboratory will begin accepting specimens for monkeypox (MPX) testing this week.
  • Mr. Hamid Erfanian, Chief Executive Officer of Enzo, stated, As a leader in testing services for many viral pathogens, Enzos clinical labs understands and supports the public health issues posed by monkeypox.
  • Enzo is concurrently applying its technical expertise in molecular diagnostics to develop a next generation monkeypox (orthopoxvirus) testing option.
  • Enzo continues to meet the needs of our clients in their efforts to provide comprehensive diagnostic testing solutions for emerging pathogens.

Verrica Pharmaceuticals Announces Start of Phase 3 Trial of VP-102 for the Treatment of Molluscum Contagiosum by Torii Pharmaceutical Co., Ltd. in Japan

Retrieved on: 
Monday, August 1, 2022
License, GLOBE, End-user license agreement, Cantharidin, Skin, U.S. Securities and Exchange Commission, Dermatology, Molluscum contagiosum, Partnership, Private Securities Litigation Reform Act, Social stigma, Sibling, Achievement, Inflammation, Wart, Disease, FDA, Company, Fomite, Pain, Therapy, Genetically modified bacteria, Prevalence, Itch, Pharmaceutical industry, Torii

WEST CHESTER, Pa., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Torii Pharmaceutical Co., Ltd. (“Torii”) dosed the first patient in its Phase 3 trial of VP-102 (referred to as TO-208 in Japan) for molluscum contagiosum in Japan, triggering an $8 million milestone payment from Torii to Verrica.

Key Points: 
  • We are pleased to see Torii dose the first patient in its Phase 3 trial of VP-102 for the treatment of molluscum contagiosum in Japan, said Ted White, Verricas President and Chief Executive Officer.
  • In March 2021 Torii exercised its option to acquire the exclusive license to develop and commercialize Verricas product candidates for the treatment of molluscum contagiosum and common warts in Japan.
  • Torii is responsible for all development activities and costs in support of obtaining regulatory approval in Japan.
  • In addition, Verrica has successfully completed a Phase 2 study ofVP-102for the treatment of common warts and a Phase 2 study ofVP-102for the treatment of external genital warts.

Verrica Pharmaceuticals Holds Type A Meeting with FDA for VP-102 for Molluscum Contagiosum

Retrieved on: 
Tuesday, June 28, 2022
Dermatology, FDA, Social stigma, Caregiver, New Drug Application, Molluscum contagiosum, Skin, GLOBE, Cantharidin, Company, Disease, Itch, Fomite, U.S. Securities and Exchange Commission, Pain, Inflammation, CMO, Food, Therapy, Wart, Genetically modified bacteria, Private Securities Litigation Reform Act, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NDA, Sibling, Pharmaceutical industry

We are pleased with our communications with the FDA leading up to and during yesterdays Type A meeting, said Ted White, Verricas President and Chief Executive Officer.

Key Points: 
  • We are pleased with our communications with the FDA leading up to and during yesterdays Type A meeting, said Ted White, Verricas President and Chief Executive Officer.
  • There are currently noFDA-approvedtreatments for molluscum, a highly contagious viral skin disease that affects approximately six million people primarily children in the United States.
  • Molluscum is caused by a pox virus that produces distinctive raised,skin-toned-to-pink-coloredlesions that can cause pain, inflammation, itching and bacterial infection.
  • Without treatment, molluscum can last for an average of 13 months, and in some cases, up to several years.

Verrica Receives Complete Response Letter from the FDA for its NDA for VP-102 as a Direct Result of Deficiencies at General Reinspection of Sterling Pharmaceuticals Services, LLC

Retrieved on: 
Wednesday, May 25, 2022
Disease, Food, U.S. Securities and Exchange Commission, Dermatology, Review, Skin, Voluntary action, Division, OAI, NDA, Private Securities Litigation Reform Act, Cantharidin, LLC, Classification, Pain, Policy, Social stigma, CRL, PAI, CMO, GLOBE, WEST, Inflammation, Company, New Drug Application, Fomite, EIR, Endpoint security, Genetically modified bacteria, FDA, VAI, Molluscum contagiosum, Therapy, Quality control, Itch, Consultant, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Sibling, Compliance, Safety, Wart, Pharmaceutical industry, Medical device, Cutlery, Agency, Sterling

WEST CHESTER, Pa., May 24, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding its New Drug Application (NDA) for VP-102 for the treatment of molluscum contagiosum (molluscum).

Key Points: 
  • The only deficiency listed in the CRL was related to the deficiencies identified at a general reinspection of Sterling Pharmaceuticals Services, LLC (Sterling), the contract manufacturing organization (CMO) that manufactures Verricas bulk solution drug product.
  • Sterling advised Verrica on May 20, 2022 that it received notice that it is on OAI status.
  • Sterlings OAI classification resulted from a week-long reinspection of the CMO conducted by FDA in February 2022.
  • Moreover, none of the issues identified by FDA during the reinspection were specific to the manufacturing of VP-102.

Verrica Pharmaceuticals Reports First Quarter 2022 Financial Results

Retrieved on: 
Monday, May 9, 2022
Social stigma, Prescription Drug User Fee Act, Table, Mission statement, Private Securities Litigation Reform Act, GAAP, Wart, Pain, Skin, Sibling, Pharmacokinetics, GLOBE, Company, NDA, Food and Drug Administration, Cantharidin, Food, Safety, Research, Patient, Immunotherapy, Review, Collaboration, FDA, Inflammation, Cancer, Itch, Therapy, Fomite, Squamous cell carcinoma, Income, Disease, Achievement, U.S. Securities and Exchange Commission, WEST, Molluscum contagiosum, Genetically modified bacteria, PDUFA, Pharmaceutical industry, Bank, Dermatology

WEST CHESTER, Pa., May 09, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the first quarter ended March 31, 2022.

Key Points: 
  • Upcoming PDUFA date of May 24, 2022 for VP-102 NDA for the treatment of molluscum
    WEST CHESTER, Pa., May 09, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the first quarter ended March 31, 2022.
  • Research and development expenses were $2.7million in the first quarter of 2022, compared to $5.4 million for the same period in 2021.
  • General and administrative expenses were $5.1million in the first quarter of 2022, compared to $6.6 million for the same period in 2021.
  • As of March 31, 2022, Verrica had aggregate cash, cash equivalents, marketable securities and restricted cash of $61.9million.

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results

Retrieved on: 
Wednesday, March 2, 2022
NDA, Table, Control, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Dermatology, Research, Genetically modified bacteria, Patient, Pharmacokinetics, Adult, Immunotherapy, Food and Drug Administration, Food, Safety, Mission statement, U.S. Securities and Exchange Commission, Skin, Molluscum contagiosum, PDUFA, Silicon, FDA, New Drug Application, Collaboration, Wart, CMC, Company, WEST, Disease, Social stigma, Squamous cell carcinoma, Pain, Inflammation, Sibling, Cantharidin, GAAP, Private Securities Litigation Reform Act, Review, Silicon Valley Bank, Insurance, Fomite, Itch, Achievement, GLOBE, Therapy, Pharmaceutical industry, Bank, Animal, Reinsurance, Chemistry

WEST CHESTER, Pa., March 02, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the fourth quarter and year ended December 31, 2021.

Key Points: 
  • The amendment provides Verrica increased financial flexibility by extending the interest-only payment period and reducing the minimum cash Verrica is required to maintain on its balance sheet.
  • Verrica reported a net loss of $9.5 million for the fourth quarter of 2021, compared to a $13.0 million loss for the same period in 2020.
  • Research and development expenses were $3.4million in the fourth quarter of 2021, compared to $2.3 million for the same period in 2020.
  • General and administrative expenses were $5.1million in the fourth quarter of 2021, compared to $9.8 million for the same period in 2020.

Verrica Pharmaceuticals Announces Acceptance by FDA of NDA Resubmission for VP-102 for the Treatment of Molluscum Contagiosum

Retrieved on: 
Wednesday, December 15, 2021
Molluscum contagiosum, U.S. Securities and Exchange Commission, Food, Social stigma, FDA, NDA, Dermatology, Company, Pain, New Drug Application, Private Securities Litigation Reform Act, Cantharidin, Skin, Sibling, Prescription Drug User Fee Act, Caregiver, Itch, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Workload, Inflammation, Disease, Therapy, PDUFA, GLOBE, Wart, Genetically modified bacteria, Fomite, Pharmaceutical industry

We are pleased that the FDA has accepted our NDA resubmission for VP-102, said Ted White, Verricas President and Chief Executive Officer.

Key Points: 
  • We are pleased that the FDA has accepted our NDA resubmission for VP-102, said Ted White, Verricas President and Chief Executive Officer.
  • In addition, Verrica has successfully completed a Phase 2 study ofVP-102for the treatment of common warts and a Phase 2 study ofVP-102for the treatment of external genital warts.
  • Without treatment, molluscum can last for an average of 13 months, and in some cases, up to several years.
  • These forward-looking statements include expectations regarding the potential timing and approval of the NDA forVP-102 [and interactions with the FDA].